Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
male (90) 90
female (88) 88
middle aged (83) 83
index medicus (79) 79
cardiovascular (71) 71
cardiac & cardiovascular systems (69) 69
aged (66) 66
stents (49) 49
treatment outcome (49) 49
internal medicine (45) 45
heart attacks (40) 40
stent (39) 39
thrombosis (39) 39
cardiology (37) 37
drug-eluting stents (33) 33
time factors (32) 32
care and treatment (31) 31
myocardial infarction (30) 30
cardiology and cardiovascular medicine (29) 29
percutaneous coronary intervention (29) 29
follow-up studies (25) 25
abridged index medicus (24) 24
angioplasty (23) 23
electrocardiography (23) 23
mortality (22) 22
risk factors (22) 22
heart attack (21) 21
transluminal angioplasty (21) 21
coronary angiography (20) 20
myocardial infarction - therapy (20) 20
artery-disease (19) 19
diabetes (19) 19
angioplasty, balloon, coronary (18) 18
denmark (18) 18
adult (17) 17
cardiac patients (17) 17
clinical outcomes (17) 17
drug-eluting stent (17) 17
myocardial infarction - mortality (17) 17
prospective studies (17) 17
risk assessment (17) 17
myocardial infarction - etiology (16) 16
patient outcomes (16) 16
sirolimus - analogs & derivatives (16) 16
aged, 80 and over (15) 15
coronary artery disease - therapy (15) 15
denmark - epidemiology (15) 15
paclitaxel (15) 15
prognosis (15) 15
reproducibility of results (15) 15
angiography (14) 14
cardiovascular disease (14) 14
coronary artery disease (14) 14
coronary vessels (14) 14
myocardial infarction - diagnosis (14) 14
safety (14) 14
sirolimus (14) 14
coronary artery disease - diagnostic imaging (13) 13
drug therapy (13) 13
fractional flow reserve (13) 13
implantation (13) 13
primary angioplasty (13) 13
research (13) 13
revascularization (13) 13
stent thrombosis (13) 13
registries (12) 12
sensitivity and specificity (12) 12
studies (12) 12
usage (12) 12
angioplasty, balloon, coronary - methods (11) 11
bare-metal stents (11) 11
comparative analysis (11) 11
coronary angiography - methods (11) 11
efficacy (11) 11
incidence (11) 11
intervention (11) 11
radiology, nuclear medicine & medical imaging (11) 11
sirolimus - administration & dosage (11) 11
clinical-outcomes (10) 10
coronary heart disease (10) 10
drug-eluting stents - adverse effects (10) 10
follow-up (10) 10
medicine, general & internal (10) 10
myocardial-infarction (10) 10
prosthesis design (10) 10
retrospective studies (10) 10
blood clot (9) 9
coronary artery disease - mortality (9) 9
disease (9) 9
medical imaging (9) 9
myocardial infarction - diagnostic imaging (9) 9
myocardial infarction - surgery (9) 9
outcomes (9) 9
platelet aggregation inhibitors - therapeutic use (9) 9
predictive value of tests (9) 9
primary pci (9) 9
stents - adverse effects (9) 9
thrombosis - etiology (9) 9
analysis (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial
by Hausenloy, DJ and Kharbanda, RK and Moller, UK and Ramlall, M and Aaroe, J and Butler, R and Bulluck, H and Clayton, T and Dana, A and Dodd, M and Engstrom, T and Evans, R and Lassen, JF and Christensen, EF and Garcia-Ruiz, JM and Gorog, DA and Hjort, J and Houghton, RF and Ibanez, B and Knight, R and Lippert, FK and Lonborg, JT and Maeng, M and Milasinovic, D and More, R and Nicholas, JM and Jensen, LO and Perkins, A and Radovanovic, N and Rakhit, RD and Ravkilde, J and Ryding, AD and Schmidt, MR and Riddervold, IS and Sorensen, HT and Stankovic, G and Varma, M and Webb, I and Terkelsen, CJ and Greenwood, JP and Yellon, DM and Botker, HE and CONDI-2 ERIC-PPCI Investigators and CONDI-2/ERIC-PPCI Investigators
LANCET, ISSN 0140-6736, 10/2019, Volume 394, Issue 10207, pp. 1415 - 1424
Background Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in... 
LIMB | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | ISCHEMIA/REPERFUSION INJURY | TASK-FORCE | SIZE | ADJUNCT | ST-SEGMENT ELEVATION | CARDIOPROTECTION | Heart failure | Myocardial infarction | Heart | Stroke | Heart attacks | Cardiac conditioning | Mortality | Medical services | Patients | Clinical outcomes | Studies | Side effects | Randomization | Reperfusion | Motivation | Ischemia | Coronary vessels | Electrocardiography | Data collection | Death | Conditioning | Heart diseases | Veins & arteries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial
by Christiansen, Evald Høj, Dr and Jensen, Lisette Okkels, DMSci and Thayssen, Per, DMSci and Tilsted, Hans-Henrik, MD and Krusell, Lars Romer, MD and Hansen, Knud Nørregaard, MD and Kaltoft, Anne, PhD and Maeng, Michael, PhD and Kristensen, Steen Dalby, Prof and Bøtker, Hans Erik, Prof and Terkelsen, Christian Juhl, DMSci and Villadsen, Anton Boel, MD and Ravkilde, Jan, DMSci and Aarøe, Jens, MD and Madsen, Morten, MSc and Thuesen, Leif, DMSci and Lassen, Jens Flensted, PhD and Scandinavian Org Randomized Trials and Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9867, pp. 661 - 669
Summary Background Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation... 
Internal Medicine | LEADERS | MEDICINE, GENERAL & INTERNAL | REVASCULARIZATION | THROMBOSIS | RISK | DENMARK HEART REGISTRY | ARTERY-DISEASE | CLINICAL-OUTCOMES | PACLITAXEL | Myocardial Infarction - epidemiology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Coronary Thrombosis - epidemiology | Humans | Acute Coronary Syndrome - mortality | Male | Retreatment - statistics & numerical data | Coated Materials, Biocompatible | Coronary Artery Disease - mortality | Absorbable Implants | Drug-Eluting Stents - adverse effects | Coronary Artery Disease - therapy | Acute Coronary Syndrome - therapy | Female | Aged | Aspirin - therapeutic use | Coronary Thrombosis - etiology | Platelet Aggregation Inhibitors - therapeutic use | Polymers | Percutaneous Coronary Intervention | Prevention | Drug-eluting stents | Comparative analysis | Health aspects | Thrombosis | Blood clot | Risk factors | Cardiovascular disease | Heart attacks | Drug therapy | Stents | Mortality | Coronary vessels
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial
by Bøtker, Hans Erik, Prof and Kharbanda, Rajesh, MD and Schmidt, Michael R, MD and Bøttcher, Morten, MD and Kaltoft, Anne K, MD and Terkelsen, Christian J, MD and Munk, Kim, MD and Andersen, Niels H, MD and Hansen, Troels M, MD and Trautner, Sven, MD and Lassen, Jens Flensted, MD and Christiansen, Evald Høj, MD and Krusell, Lars R, MD and Kristensen, Steen D, MD and Thuesen, Leif, MD and Nielsen, Søren S, MD and Rehling, Michael, MD and Sørensen, Henrik Toft, Prof and Redington, Andrew N, Prof and Nielsen, Torsten T, Prof
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9716, pp. 727 - 734
Summary Background Remote ischaemic preconditioning attenuates cardiac injury at elective surgery and angioplasty. We tested the hypothesis that remote... 
Internal Medicine | MORTALITY | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | PRECONDITIONING PROTECTS | THROMBUS ASPIRATION | SIZE | THROMBECTOMY | INJURY | REPERFUSION | ARTERY | DEPENDENT MECHANISM | Angioplasty, Balloon, Laser-Assisted | Prospective Studies | Humans | Middle Aged | Tomography, Emission-Computed, Single-Photon | Male | Angioplasty, Balloon, Coronary | Aspirin - administration & dosage | Myocardial Infarction - therapy | Troponin T - blood | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Electrocardiography | Ticlopidine - administration & dosage | Female | Technetium Tc 99m Sestamibi | Drug Therapy, Combination | Radiopharmaceuticals | Echocardiography | Myocardium - pathology | Treatment Outcome | Hospitalization | Ticlopidine - analogs & derivatives | Immunoglobulin Fab Fragments - administration & dosage | Antibodies, Monoclonal - administration & dosage | Arm - blood supply | Ischemic Preconditioning, Myocardial - methods | Myocardial Reperfusion Injury - prevention & control | Care and treatment | Research | Angioplasty | Health aspects | Heart attack | Heart failure | Emergency medical care | Heart attacks | Biomedical research | Statistical analysis | Cardiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets
by Würtz, Morten, MS and Grove, Erik L., MD and Wulff, Lise N., MS and Kaltoft, Anne K., MD, PhD and Tilsted, Hans H., MD and Jensen, Lisette O., MD, PhD and Hvas, Anne-Mette, MD, PhD and Kristensen, Steen D., MD, DMSc
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2010, Volume 3, Issue 8, pp. 828 - 835
Objectives This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST).... 
Cardiovascular | aspirin | platelet function tests | stent thrombosis | immature platelets | platelet aggregation | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | FUNCTION TESTS | ACUTE CORONARY SYNDROMES | DRUG-ELUTING STENT | HIGH-RISK PATIENTS | CLOPIDOGREL | THERAPY | IMPLANTATION | RESISTANCE | ARTERY-DISEASE | Angioplasty, Balloon, Coronary - instrumentation | Humans | Middle Aged | Male | Coronary Artery Disease - blood | Case-Control Studies | Angioplasty, Balloon, Coronary - adverse effects | Flow Cytometry | Time Factors | Platelet Function Tests | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Retrospective Studies | Thrombosis - blood | Thrombosis - prevention & control | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Stents | Drug Resistance | Linear Models | Treatment Outcome | Biomarkers - blood | Coronary Artery Disease - drug therapy | Chi-Square Distribution | Medication Adherence | Coronary Artery Disease - therapy | Platelet Count | Blood Platelets - metabolism | Thrombosis - etiology | Denmark | P-Selectin - blood | Aged | Thromboxane B2 - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial
by Raungaard, Bent, Dr and Jensen, Lisette Okkels, DMSci and Tilsted, Hans-Henrik, MD and Christiansen, Evald Høj, PhD and Maeng, Michael, PhD and Terkelsen, Christian Juhl, DMSci and Krusell, Lars Romer, MD and Kaltoft, Anne, PhD and Kristensen, Steen Dalby, Prof and Bøtker, Hans Erik, Prof and Thuesen, Leif, DMSci and Aarøe, Jens, MD and Jensen, Svend Eggert, PhD and Villadsen, Anton Boel, MD and Thayssen, Per, DMSci and Veien, Karsten Tange, MD and Hansen, Knud Nørregaard, MD and Junker, Anders, MD and Madsen, Morten, MSc and Ravkilde, Jan, DMSci and Lassen, Jens Flensted, PhD and Scandinavian Org Randomized Trials and Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT)
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9977, pp. 1527 - 1535
Summary Background New-generation drug-eluting coronary stents have reduced the risk of coronary events, especially in patients with complex disease or... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | THROMBOSIS | SAFETY | BARE-METAL STENTS | OPEN-LABEL | ALL-COMERS | ARTERY-DISEASE | CLINICAL-OUTCOMES | SIROLIMUS | PACLITAXEL | Drug-Eluting Stents | Sirolimus - analogs & derivatives | Humans | Middle Aged | Male | Treatment Outcome | Coated Materials, Biocompatible | Equipment Design | Absorbable Implants | Sirolimus - administration & dosage | Myocardial Ischemia - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Denmark | Female | Aged | Myocardial Ischemia - mortality | Polymers | Immunosuppressive Agents - administration & dosage | Percutaneous Coronary Intervention | Transluminal angioplasty | Polymer industry | Cardiac patients | Stent (Surgery) | Heart attacks | Cardiology | Stents | Mortality | Coronary vessels
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
by Rasmussen, Klaus, MD and Maeng, Michael, MD and Kaltoft, Anne, MD and Thayssen, Per, MD and Kelbæk, Henning, MD and Tilsted, Hans Henrik, MD and Abildgaard, Ulrik, MD and Christiansen, Evald Høj, MD and Engstrøm, Thomas, MD and Krusell, Lars Romer, MD and Ravkilde, Jan, MD and Hansen, Peter Riis, MD and Hansen, Knud Nørregaard, MD and Abildstrøm, Steen Zabell, MD and Aarøe, Jens, MD and Jensen, Jan Skov, MD and Kristensen, Steen Dalby, MD and Bøtker, Hans Erik, Prof and Madsen, Morten, MSc and Johnsen, Søren Paaske, MD and Jensen, Lisette Okkels, MD and Sørensen, Henrik Toft, Prof and Thuesen, Leif, MD and Lassen, Jens Flensted, Dr and SORT OUT III Study Grp and SORT OUT III study group
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9720, pp. 1090 - 1099
Summary Background In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent... 
Internal Medicine | DRUG | MEDICINE, GENERAL & INTERNAL | THROMBOSIS | IMPLANTATION | LARGE 2-INSTITUTIONAL COHORT | ARTERY LESIONS | DISEASE | ACUTE MYOCARDIAL-INFARCTION | FOLLOW-UP | ENDEAVOR | OUTCOMES | Single-Blind Method | Sirolimus - analogs & derivatives | Humans | Middle Aged | Coronary Restenosis - prevention & control | Male | Treatment Outcome | Angioplasty, Balloon, Coronary | Drug-Eluting Stents - adverse effects | Retreatment | Thrombosis - etiology | Coronary Disease - therapy | Female | Aged | Myocardial Infarction - etiology | Sirolimus - adverse effects | Care and treatment | Patient outcomes | Dosage and administration | Coronary heart disease | Health aspects | Immunosuppressive agents | Stent (Surgery) | Studies | Intervention | Heart attacks | Medical imaging | Angioplasty | Cardiovascular disease | Clinical medicine | Acute coronary syndromes | Stents | Blood clots
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions
by Jensen, Lisette Okkels, MD, PhD and Maeng, Michael, MD, PhD and Kaltoft, Anne, MD, PhD and Thayssen, Per, MD, DMSci and Hansen, Hans Henrik Tilsted, MD and Bottcher, Morten, MD, PhD and Lassen, Jens Flensted, MD, PhD and Krussel, Lars Romer, MD, DMSci and Rasmussen, Klaus, MD, DMSci and Hansen, Knud Noerregaard, MD and Pedersen, Lars, MSc and Johnsen, Soeren Paaske, MD, PhD and Soerensen, Henrik Toft, MD, DMSci, PhD and Thuesen, Leif, MD, DMSci
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2007, Volume 50, Issue 5, pp. 463 - 470
Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions Lisette Okkels Jensen, Michael Mæng, Anne... 
Cardiovascular | Internal Medicine | UNCOATED STENTS | REVASCULARIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | IMPLANTATION | SAFETY | POOLED ANALYSIS | COHORT | OUTCOMES | CLINICAL-PRACTICE | ARTERY-DISEASE | Stents - statistics & numerical data | Myocardial Infarction - epidemiology | Drug Delivery Systems - statistics & numerical data | Prospective Studies | Coronary Thrombosis - epidemiology | Follow-Up Studies | Risk Assessment | Comorbidity | Humans | Middle Aged | Male | Cause of Death | Incidence | Outcome and Process Assessment (Health Care) | Denmark - epidemiology | Female | Registries | Aged | Causality | Stents - adverse effects | Drug Delivery Systems - adverse effects | Heart diseases | Thrombosis | Stent (Surgery) | Blood clot | Mortality | Drug therapy | Cardiology | Epidemiology | Heart attacks | Hospitals | Stents | Coronary vessels
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial
by Maeng, Michael, Dr and Tilsted, Hans Henrik, MD and Jensen, Lisette Okkels, MD and Krusell, Lars Romer, MD and Kaltoft, Anne, MD and Kelbæk, Henning, MD and Villadsen, Anton B, MD and Ravkilde, Jan, MD and Hansen, Knud Nørregaard, MD and Christiansen, Evald Høj, MD and Aarøe, Jens, MD and Jensen, Jan Skov, Prof and Kristensen, Steen Dalby, Prof and Bøtker, Hans Erik, Prof and Thuesen, Leif, MD and Madsen, Morten, MSc and Thayssen, Per, MD and Sørensen, Henrik Toft, Prof and Lassen, Jens Flensted, MD
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9934, pp. 2047 - 2056
Summary Background In head-to-head comparisons of coronary drug-eluting stents, the primary endpoint is traditionally assessed after 9–12 months. However, the... 
Internal Medicine | ANGIOGRAPHIC OUTCOMES | MEDICINE, GENERAL & INTERNAL | REVASCULARIZATION | SCANDINAVIAN ORGANIZATION | SAFETY | BARE-METAL STENTS | NON-INFERIORITY TRIAL | FOLLOW-UP | INTERVENTION | ENDEAVOR-III | ARTERY-DISEASE | Single-Blind Method | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Coronary Restenosis - prevention & control | Cytostatic Agents - administration & dosage | Male | Treatment Outcome | Cytostatic Agents - therapeutic use | Drug-Eluting Stents - adverse effects | Cytostatic Agents - adverse effects | Sirolimus - administration & dosage | Percutaneous Coronary Intervention - instrumentation | Coronary Artery Disease - therapy | Time Factors | Female | Aged | Coronary Thrombosis - etiology | Myocardial Infarction - etiology | Research Design | Sirolimus - adverse effects | Complications and side effects | Usage | Drug-eluting stents | Zotarolimus | Dosage and administration | Research | Health aspects | Comparative analysis | Stent (Surgery) | Transluminal angioplasty | Heart | Cardiology | Studies | Heart attacks | Angina pectoris | Stents | Coronary vessels | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Safety and efficacy of everolimus- versus sirolimus-eluting stents 5-year results from SORT OUT IV
by Jensen, Lisette Okkels and Thayssen, Per and Christiansen, Evald Høj and Maeng, Michael and Ravkilde, Jan and Hansen, Knud Nørregaard and Hansen, Henrik Steen and Krusell, Lars and Kaltoft, Anne and Tilsted, Hans Henrik and Berencsi, Klara and Junker, Anders and Lassen, Jens Flensted and SORT OUT IV Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2016, Volume 67, Issue 7, pp. 751 - 762
Background Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting stents (SES) are unknown. Objectives This study... 
very late definite stent thrombosis | percutaneous coronary intervention | outcome | drug-eluting stent(s) | BIODEGRADABLE POLYMER | CARDIAC & CARDIOVASCULAR SYSTEMS | NON-INFERIORITY TRIAL | FOLLOW-UP | RANDOMIZED CONTROLLED-TRIAL | PACLITAXEL | TERM CLINICAL-OUTCOMES | UNSELECTED PATIENTS | SUPERIORITY TRIAL | DURABLE POLYMER | CORONARY-ARTERY-DISEASE | Single-Blind Method | Coronary Artery Disease - surgery | Drug-Eluting Stents | Survival Rate - trends | Everolimus - pharmacology | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Postoperative Complications - epidemiology | Prosthesis Design | Sirolimus - pharmacology | Incidence | Time Factors | Percutaneous Coronary Intervention - methods | Denmark - epidemiology | Female | Retrospective Studies | Immunosuppressive Agents - pharmacology | Studies | Confidence intervals | Heart attacks | Medical imaging | Coronary vessels | Mortality | Cardiovascular disease | Acute coronary syndromes | Stents | Thrombosis | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials
by Burzotta, Francesco and De Vita, Maria and Gu, Youlan L and Isshiki, Takaaki and Lefevre, Thierry and Kaltoft, Anne and Dudek, Dariusz and Sardella, Gennaro and Orrego, Peo Silva and Antoniucci, David and De Luca, Leonardo and Biondi-Zoccai, Giuseppe G. L and Crea, Filippo and Zijlstra, Felix
European Heart Journal, ISSN 0195-668X, 09/2009, Volume 30, Issue 18, pp. 2193 - 2203
Thrombectomy in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) is associated to better myocardial... 
Long-term clinical outcome | ST-elevation myocardial infarction | Primary PCI | INTRAVENOUS THROMBOLYTIC THERAPY | RANDOMIZED-TRIALS | NO-REFLOW PHENOMENON | UMCG Approved | THROMBUS-ASPIRATION | SEGMENT-ELEVATION | Thrombectomy | PERCUTANEOUS CORONARY INTERVENTION | RHEOLYTIC THROMBECTOMY | INTRACORONARY THROMBECTOMY | PRIMARY ANGIOPLASTY | DISTAL EMBOLIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | NO-REFLOW | FOLLOW-UP | SEGMENT RESOLUTION | Myocardial Infarction - surgery | Myocardial Infarction - drug therapy | Humans | Middle Aged | Thrombectomy - methods | Kaplan-Meier Estimate | Myocardial Revascularization - methods | Female | Male | Aged | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights